FindTrial
Sign In

The effect of percutaneous lung centesis and thoracoscopic surgery on the circulating tumor cells of lung cancer

The effect of percutaneous lung centesis and thoracoscopic surgery on the circulating tumor cells of lung cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800018775
Enrollment
Unknown
Registered
2018-10-09
Start date
2018-10-08
Completion date
Unknown
Last updated
2018-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Group 1:percutaneous pulmonary centesis
Group 2:VATS

Sponsors

The 113th Hospital of PLA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Lung cancer patients aged 18 to 80 who will undergo percutaneous pulmonary centesis and VATS.

Exclusion criteria

Exclusion criteria: The patients in crictical conditions with unstable vital signs.

Design outcomes

Primary

MeasureTime frame
CTC count;—

Countries

China

Contacts

Public ContactWei-Liang Li

Department of Respiratory and Critical Care Medicine, the 113th Hospital of PLA

ipec2012@126.com+86 13906688746

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026